These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27260150)

  • 1. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2016 Aug; 44(8):1364-71. PubMed ID: 27260150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
    Kosoglou T; Kumar B; Statkevich P; Schiller JE; Kantesaria B; Hanson ME; Sisk CM; Cutler DL
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
    Itkonen MK; Tornio A; Filppula AM; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2018 Sep; 104(3):495-504. PubMed ID: 29171020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.
    Kim SJ; Yoshikado T; Ieiri I; Maeda K; Kimura M; Irie S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2016 Oct; 44(10):1622-32. PubMed ID: 27457785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Niemi M; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
    Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
    Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H; Wu JT; Palmer R; McLean L
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
    Aquilante CL; Wempe MF; Spencer SH; Kosmiski LA; Predhomme JA; Sidhom MS
    Pharmacotherapy; 2013 Sep; 33(9):1000-7. PubMed ID: 23712614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
    Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
    Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gemfibrozil on the pharmacokinetics of pioglitazone.
    Deng LJ; Wang F; Li HD
    Eur J Clin Pharmacol; 2005 Dec; 61(11):831-6. PubMed ID: 16283275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.